Vaishali Sanchorawala, MD Hear my name
Boston University Chobanian & Avedisian School of Medicine
Hematology & Medical Oncology

MBBS, Seth G.S. Medical College

Pronouns: she/her/hers

72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)

Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.

Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Chobanian and Avedisian School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.

Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.

Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.

She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.

Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.

Diversity, Equity, Inclusion and Accessibility

I stand firmly committed to diversity, equity, inclusion, and justice as a core value of my professional and personal life. I have a strong commitment to making a difference to people from underprivileged and marginalized communities. I strive to bridge access to the most cutting-edge diagnostic modalities and treatments for members of all underrepresented groups—e.g., ethnic, racial, religious, and sexual minorities, among others.

I also support diversity and equity through my research efforts, by studying racial and ethnic inequalities that are pervasive within the field of medicine. In particular, I am struck by the low representation of minorities in clinical trials, despite having a disproportionately higher risk of certain diseases. I mentored a fellow to conduct a study investigating racial and ethnic disparities in a rare plasma cell disorder called AL amyloidosis, and found that differences in health outcomes among minorities were largely explained by lower educational level and later recognition of disease, rather than race and ethnicity itself. We concluded that, in order to mitigate disparities in this rare disease, earlier disease detection and concerted efforts to reduce economic and/or language barriers are key.

My influence extends beyond the groundbreaking and paradigm-shifting work in the field of amyloidosis. In addition to my scientific achievements, I have an interest in working in charity organizations. I help cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteer regularly at “Cradles to Crayons” charity, non-profit organization. I consistently seek opportunities to understand, respect and serve communities in need.

Associate Director
Boston University Chobanian & Avedisian School of Medicine
Amyloidosis Center

Boston University
BU-BMC Cancer Center

Boston Medical Center
Stem Cell Transplantation Program
Hematology & Medical Oncology

International Society of Amyloidosis

Executive committee
Amyloidosis Research Consortium

Associate Editor
Amyloid: The Journal of Protein Folding disorders

SPORE in Multiple Myeloma
06/01/2021 - 05/31/2023 (Key Person / Mentor)
Dana-Farber Cancer Institute NIH NCI

Evaluating Plasma Neurofilament Light Chain as an Early Biomarker for Polyneuropathy in V122I Hereditary Transthyretin Amyloidosis
01/01/2022 - 12/31/2022 (Key Person / Mentor)
PI: K. H. Vincent Lau, MD
Amyloidosis Foundation

A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto
09/28/2012 - 09/27/2022 (PI)
Millennium Pharmaceuticals, Inc.

Defining a molecular signature of cardiac tissue dysfunction in systemic immunoglobulin light-chain amyloidosis
07/01/2020 - 06/30/2022 (Key Person / Mentor)
PI: Camille Edwards, MD
American Society of Hematology

A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis
03/01/2012 - 02/28/2021 (PI)
Celgene Corporation

Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2020 (Co-Investigator)
The Brigham and Women's Hospital, Inc. NIH NHLBI

A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium

Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis
09/04/2012 - 09/09/2019 (Subcontract PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc

A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis
05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited, d/b/a Prothena Therapeutics Limited

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further
04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.

Showing 10 of 17 results. Show All Results

11/17/2017 - 11/17/2026 (PI)
Janssen Research and Development, LLC

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis
05/19/2022 - 05/18/2025 (PI)
Janssen Research and Development, LLC

CAEL-101 301: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta
09/23/2020 - 09/22/2024 (PI)
Caelum Biosciences, Inc.

CAEL-101 302: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta
09/23/2020 - 09/22/2024 (PI)
Caelum Biosciences, Inc.

NEOD001-301: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
06/23/2021 - 06/22/2024 (PI)
Prothena Biosciences Limited

07/23/2020 - 01/22/2024 (PI)
Weill Cornell Medical College Janssen Scientific A

DFCI 19-291: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone…
12/23/2019 - 12/22/2023 (PI)
Dana Farber Cancer Institute Millennium Pharmaceu

STI-6129-001: A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
12/01/2020 - 11/30/2023 (PI)
Sorrento Therapeutics, Inc.

A Phase II randomized single-blind study to evaluate the activity and safety of low dose oral…
04/23/2020 - 04/22/2023 (PI)
Karyopharm Therapeutics Inc.

Oncopeptides: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL…
11/21/2019 - 11/20/2022 (PI)
Oncopeptides AB

Showing 10 of 16 results. Show All Results


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Edwards CV, Ferri GM, Villegas-Galaviz J, Ghosh S, Bawa PS, Wang F, Klimtchuk E, Ajayi TB, Morgan GJ, Prokaeva T, Staron A, Ruberg FL, Sanchorawala V, Giadone RM, Murphy GJ. Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition. bioRxiv. 2024 Mar 16.View Related Profiles. PMID: 38558967; PMCID: PMC10980073; DOI: 10.1101/2024.03.14.584987;
  2. Anand SK, Sanchorawala V, Verma A. Systemic Amyloidosis and Kidney Transplantation: An Update. Semin Nephrol. 2024 Mar 14; 151496.View Related Profiles. PMID: 38490903; DOI: 10.1016/j.semnephrol.2024.151496;
  3. Datar Y, Clerc OF, Cuddy SAM, Kim S, Taylor A, Neri JC, Benz DC, Bianchi G, Yee AJ, Sanchorawala V, Ruberg FL, Landau H, Liao R, Kijewski MF, Jerosch-Herold M, Kwong RY, Di Carli MF, Falk RH, Dorbala S. Quantification of Right Ventricular Amyloid Burden with 18F-florbetapir PET/CT and its Association with Right Ventricular Dysfunction and Outcomes in Light-Chain Amyloidosis. Eur Heart J Cardiovasc Imaging. 2024 Jan 09.View Related Profiles. PMID: 38193678
  4. Lau KHV, Prokaeva T, Zheng L, Doros G, Kaku MC, Spencer B, Berk J, Sanchorawala V. Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis. Amyloid. 2023 Dec 11; 1-3.View Related Profiles. PMID: 38073425
  5. Gustine JN, Staron A, Mendelson L, Joshi T, Gopal DM, Siddiqi OK, Ruberg FL, Sanchorawala V. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Adv. 2023 Oct 24; 7(20):6080-6091.View Related Profiles. PMID: 37581513; PMCID: PMC10582303; DOI: 10.1182/bloodadvances.2023010324;
  6. Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, Liedtke M, Sanchorawala V, Schönland S, Wechalekar A, Zonder JA, Palladini G, Walling J, Guthrie S, Nie C, Karp C, Jin Y, Kinney GG, Merlini G. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. 2023 Oct 05; 142(14):1208-1218. PMID: 37366170; PMCID: PMC10644097; DOI: 10.1182/blood.2022019406;
  7. Sarosiek S, Lee MH, Doros G, Edwards CV, Quillen K, Brauneis D, Shelton AC, Sanchorawala V, Sloan JM. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study. Transplant Cell Ther. 2023 Nov; 29(11):695.e1-695.e7.View Related Profiles. PMID: 37607644
  8. Ghosh S, Villacorta-Martin C, Lindstrom-Vautrin J, Kenney D, Golden CS, Edwards CV, Sanchorawala V, Connors LH, Giadone RM, Murphy GJ. Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures. Amyloid. 2023 Dec; 30(4):379-393.View Related Profiles. PMID: 37439769; DOI: 10.1080/13506129.2023.2224494;
  9. Adebayo AL, Rowan KE, Sanchorawala V, Boedicker MN, Boedicker DD. Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients' narratives on medical students' knowledge, attitudes, and behavioral intent. MedEdPublish (2016). 2023; 13:32. PMID: 37753389; PMCID: PMC10518845; DOI: 10.12688/mep.19631.1;
  10. Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes. Haematologica. 2023 Jun 01; 108(6):1680-1684.View Related Profiles. PMID: 36546447; PMCID: PMC10230421; DOI: 10.3324/haematol.2022.282264;
Showing 10 of 240 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 240 publications over 27 distinct years, with a maximum of 19 publications in 2020 and 2022


2015 Research mentor award
2015 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2011 Research Mentoring Award nomination
2011 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2007-2009 Robert Dawson Evans Clinician Award
2000 IBMTR/ABMTR: Mortimer M. Bortin Award for best abstract
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Amyloidosis [C18.452.845.500]
Stem cell transplantation
Clinical research

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

72 East Concord Street, K-503
Boston MA 02118
Google Map

Sanchorawala's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department